Cargando…

Impacts of a Brazilian pharmaceutical program on the health of chronic patients

OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian Popular Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: de Almeida, Aléssio Tony Cavalcanti, de Sá, Edvaldo Batista, Vieira, Fabiola Sulpino, Benevides, Rodrigo Pucci de Sá e
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Saúde Pública da Universidade de São Paulo 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390690/
https://www.ncbi.nlm.nih.gov/pubmed/30726501
http://dx.doi.org/10.11606/S1518-8787.2019053000733
_version_ 1783398188908019712
author de Almeida, Aléssio Tony Cavalcanti
de Sá, Edvaldo Batista
Vieira, Fabiola Sulpino
Benevides, Rodrigo Pucci de Sá e
author_facet de Almeida, Aléssio Tony Cavalcanti
de Sá, Edvaldo Batista
Vieira, Fabiola Sulpino
Benevides, Rodrigo Pucci de Sá e
author_sort de Almeida, Aléssio Tony Cavalcanti
collection PubMed
description OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian Popular Pharmacy Program, the statistical model of fixed-effect difference in differences was used, considering: the divisions Rede Própria (RP – Proprietary Network) and Rede Conveniada (RC – Partnership Network); the exposure time of the municipality to the program; intramunicipal density, measured by the number of accredited establishments; and the coverage spillover effect into patients from nonparticipating municipalities. Data from 5,566 municipalities were used, for the period from 2003 to 2016, including: (i) administrative records of the PFPB, Sistema de Informações sobre Mortalidade (SIM – Information System on Mortality), and Sistema de Informações Hospitalares (SIH – Hospital Information System); ii) other health data managed by the Departamento de Informática do SUS (DATASUS – Department of Informatics of SUS); iii) sociodemographic data produced by the Brazilian Institute of Geography and Statistics (IBGE); and iv) data from the Relação Anual de Informações Sociais (RAIS – Annual List of Social Information). RESULTS: The expansion of access to medicines for treatment of hypertension and diabetes resulted in a meaningful and statistically significant reduction (p < 0.05) of the number of hospitalizations and deaths by these diseases, in an average annual rate of 27.6% and 8.0%, respectively. The observed impacts were induced by the partnership network, highlighting the density of establishments per 100,000 inhabitants and, above all, the exposure time of the municipality to the program as relevant to the effect. Evidence of a spillover effect and of the maintenance of impacts on different age groups, especially older people, were also observed. CONCLUSIONS: The strategy to expand access to medicines through the PFPB was effective in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the investigated period. Better understanding the impacts of the program is important to improve the pharmaceutical care policy, to ensure access to cost-effective treatments.
format Online
Article
Text
id pubmed-6390690
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Faculdade de Saúde Pública da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-63906902019-03-01 Impacts of a Brazilian pharmaceutical program on the health of chronic patients de Almeida, Aléssio Tony Cavalcanti de Sá, Edvaldo Batista Vieira, Fabiola Sulpino Benevides, Rodrigo Pucci de Sá e Rev Saude Publica Original Article OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian Popular Pharmacy Program, the statistical model of fixed-effect difference in differences was used, considering: the divisions Rede Própria (RP – Proprietary Network) and Rede Conveniada (RC – Partnership Network); the exposure time of the municipality to the program; intramunicipal density, measured by the number of accredited establishments; and the coverage spillover effect into patients from nonparticipating municipalities. Data from 5,566 municipalities were used, for the period from 2003 to 2016, including: (i) administrative records of the PFPB, Sistema de Informações sobre Mortalidade (SIM – Information System on Mortality), and Sistema de Informações Hospitalares (SIH – Hospital Information System); ii) other health data managed by the Departamento de Informática do SUS (DATASUS – Department of Informatics of SUS); iii) sociodemographic data produced by the Brazilian Institute of Geography and Statistics (IBGE); and iv) data from the Relação Anual de Informações Sociais (RAIS – Annual List of Social Information). RESULTS: The expansion of access to medicines for treatment of hypertension and diabetes resulted in a meaningful and statistically significant reduction (p < 0.05) of the number of hospitalizations and deaths by these diseases, in an average annual rate of 27.6% and 8.0%, respectively. The observed impacts were induced by the partnership network, highlighting the density of establishments per 100,000 inhabitants and, above all, the exposure time of the municipality to the program as relevant to the effect. Evidence of a spillover effect and of the maintenance of impacts on different age groups, especially older people, were also observed. CONCLUSIONS: The strategy to expand access to medicines through the PFPB was effective in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the investigated period. Better understanding the impacts of the program is important to improve the pharmaceutical care policy, to ensure access to cost-effective treatments. Faculdade de Saúde Pública da Universidade de São Paulo 2019-01-18 /pmc/articles/PMC6390690/ /pubmed/30726501 http://dx.doi.org/10.11606/S1518-8787.2019053000733 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
de Almeida, Aléssio Tony Cavalcanti
de Sá, Edvaldo Batista
Vieira, Fabiola Sulpino
Benevides, Rodrigo Pucci de Sá e
Impacts of a Brazilian pharmaceutical program on the health of chronic patients
title Impacts of a Brazilian pharmaceutical program on the health of chronic patients
title_full Impacts of a Brazilian pharmaceutical program on the health of chronic patients
title_fullStr Impacts of a Brazilian pharmaceutical program on the health of chronic patients
title_full_unstemmed Impacts of a Brazilian pharmaceutical program on the health of chronic patients
title_short Impacts of a Brazilian pharmaceutical program on the health of chronic patients
title_sort impacts of a brazilian pharmaceutical program on the health of chronic patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390690/
https://www.ncbi.nlm.nih.gov/pubmed/30726501
http://dx.doi.org/10.11606/S1518-8787.2019053000733
work_keys_str_mv AT dealmeidaalessiotonycavalcanti impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients
AT desaedvaldobatista impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients
AT vieirafabiolasulpino impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients
AT benevidesrodrigopuccidesae impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients